Skip to main content

Graves' Disease

1
Pipeline Programs
3
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
CFZ533Phase 21 trial
Active Trials
NCT02713256Completed15Est. Apr 2017
Immunovant
ImmunovantDURHAM, NC
3 programs
IMVT-1402PHASE_21 trial
IMVT-1402PHASE_21 trial
IMVT-1402PHASE_21 trial
Active Trials
NCT07286006Enrolling By Invitation372Est. Mar 2030
NCT07018323Recruiting210Est. May 2027
NCT06727604Recruiting240Est. Jun 2028
Novartis
NovartisBASEL, Switzerland
1 program
CFZ533PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
ImmunovantIMVT-1402
ImmunovantIMVT-1402
ImmunovantIMVT-1402
SandozCFZ533

Clinical Trials (4)

Total enrollment: 837 patients across 4 trials

NCT07286006ImmunovantIMVT-1402

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Start: Jan 2026Est. completion: Mar 2030372 patients
Phase 2Enrolling By Invitation
NCT07018323ImmunovantIMVT-1402

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Start: Jun 2025Est. completion: May 2027210 patients
Phase 2Recruiting
NCT06727604ImmunovantIMVT-1402

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Start: Dec 2024Est. completion: Jun 2028240 patients
Phase 2Recruiting
NCT02713256SandozCFZ533

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Start: Apr 2016Est. completion: Apr 201715 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 837 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.